Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Saúde e Desenvolvimento Humano |
Texto Completo: | https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487 |
Resumo: | Depression is one of the major mental illnesses of the century, being one of the major causes of morbidity and disability. Antidepressants (AD) currently on the market seem to increase concentrations of monoamines in the brain (dopamine, noradrenaline and serotonin). However, ADs have unwanted side effects, and this has motivated research on drugs with differentiated mechanisms of action. It is known that in the depressive state the circadian cycle is altered, resulting in damages in the sleep phases and wake, and consequently in the concentrations of melatonin (MEL). MEL is an important hormone related to the synchronization of the circadian cycle, and is closely linked with depressive states and insomnia. With these data, the objective of this work was to investigate through a literature review, the relationship of the melatoninergic system with depression and treatment with agomelatine. As a method, studies related to the descriptors: “depression and melatonin” were searched in the search platforms:”Scielo, PubMed and BVS (lilacs)”. The results obtained show that, of the studies evaluated, they mostly refers to agomelatine, an AD drug analogous to melatonin. AGOM has promising results in clinical and preclinical research to treat problems related to insomnia and depression, representing an innovation in drugs for this therapeutic purpose. It was concluded that the melatoninergic system is closely linked to depressive states and agomelatine presents as a promising drug for the treatment of depression associated with sleep and virile cycle disorders. |
id |
UNILASALLE-6_479543f128872881fe0ead81b238711c |
---|---|
oai_identifier_str |
oai:ojs.revistas.unilasalle.edu.br:article/5487 |
network_acronym_str |
UNILASALLE-6 |
network_name_str |
Saúde e Desenvolvimento Humano |
repository_id_str |
|
spelling |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature reviewDepressão e as implicações do sistema de Melatonina e tratamento com Agomelatina: uma revisão de literaturaDepression; Melatonin; AgomelatineNeurociênciasDepressão; Melatonina; AgomelatinaDepression is one of the major mental illnesses of the century, being one of the major causes of morbidity and disability. Antidepressants (AD) currently on the market seem to increase concentrations of monoamines in the brain (dopamine, noradrenaline and serotonin). However, ADs have unwanted side effects, and this has motivated research on drugs with differentiated mechanisms of action. It is known that in the depressive state the circadian cycle is altered, resulting in damages in the sleep phases and wake, and consequently in the concentrations of melatonin (MEL). MEL is an important hormone related to the synchronization of the circadian cycle, and is closely linked with depressive states and insomnia. With these data, the objective of this work was to investigate through a literature review, the relationship of the melatoninergic system with depression and treatment with agomelatine. As a method, studies related to the descriptors: “depression and melatonin” were searched in the search platforms:”Scielo, PubMed and BVS (lilacs)”. The results obtained show that, of the studies evaluated, they mostly refers to agomelatine, an AD drug analogous to melatonin. AGOM has promising results in clinical and preclinical research to treat problems related to insomnia and depression, representing an innovation in drugs for this therapeutic purpose. It was concluded that the melatoninergic system is closely linked to depressive states and agomelatine presents as a promising drug for the treatment of depression associated with sleep and virile cycle disorders.A depressão é uma das principais doenças mentais do século, sendo uma das maiores causas de morbidade e invalidez. Os antidepressivos (AD) atualmente no mercado buscam aumentar as concentrações de monoaminas no encéfalo (dopamina, noradrenalina e serotonina). Todavia, os AD possuem efeitos colaterais indesejados, e isto tem motivado a pesquisa sobre medicamentos com mecanismos de ação diferenciados. Sabe- se, que no estado depressivo o ciclo circadiano é alterado, resultando em prejuízos nos estados de sono e vigília e consequentemente nas concentrações de melatonina (MEL). A MEL é um importante hormônio relacionado com a sincronização do ciclo circadiano, e está intimamente ligada com estados depressivos e insônia. Com estes dados, o objetivo do trabalho foi investigar através de uma revisão de literatura, a relação do sistema melatoninérgico com a depressão e seu tratamento com agomelatina (AGOM). Como método, foram pesquisados estudos relacionados aos descritores: “depressão e melatonina”, nas plataformas de busca: ”Scielo, PubMed e BVS (lilacs)”. Os resultados obtidos mostram, que dos estudos avaliados, em sua maioria cita a agomelatina, um fármaco AD análogo à melatonina. A AGOM possui resultados promissores em pesquisas clínicas e pré-clínicas para tratar problemas relacionados a insônia e a depressão, representando uma inovação nos fármacos com esta finalidade terapêutica. Concluiu-se, que o sistema melatoninérgico está intimamente ligado a estados depressivos e a agomelatina se apresenta como um fármaco promissor para o tratamento da depressão associada com alterações do ciclo sono e vigília.Universidade LaSalle - Unilasalle Canoasde Souza, Jackeline Martins EberhardtLazzaretti, Camilla2021-02-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/548710.18316/sdh.v9i1.5487Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021)Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021)2317-8582reponame:Saúde e Desenvolvimento Humanoinstname:Universidade La Salle (UNILASALLE)instacron:UNILASALLEporhttps://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487/pdfDireitos autorais 2021 Saúde e Desenvolvimento Humanoinfo:eu-repo/semantics/openAccess2022-03-23T16:14:39Zoai:ojs.revistas.unilasalle.edu.br:article/5487Revistahttp://www.revistas.unilasalle.edu.br/index.php/saude_desenvolvimentohttps://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/oaisdh@unilasalle.edu.br2317-85822317-8582opendoar:2022-03-23T16:14:39Saúde e Desenvolvimento Humano - Universidade La Salle (UNILASALLE)false |
dc.title.none.fl_str_mv |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review Depressão e as implicações do sistema de Melatonina e tratamento com Agomelatina: uma revisão de literatura |
title |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review |
spellingShingle |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review de Souza, Jackeline Martins Eberhardt Depression; Melatonin; Agomelatine Neurociências Depressão; Melatonina; Agomelatina |
title_short |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review |
title_full |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review |
title_fullStr |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review |
title_full_unstemmed |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review |
title_sort |
Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review |
author |
de Souza, Jackeline Martins Eberhardt |
author_facet |
de Souza, Jackeline Martins Eberhardt Lazzaretti, Camilla |
author_role |
author |
author2 |
Lazzaretti, Camilla |
author2_role |
author |
dc.contributor.none.fl_str_mv |
|
dc.contributor.author.fl_str_mv |
de Souza, Jackeline Martins Eberhardt Lazzaretti, Camilla |
dc.subject.none.fl_str_mv |
|
dc.subject.por.fl_str_mv |
Depression; Melatonin; Agomelatine Neurociências Depressão; Melatonina; Agomelatina |
topic |
Depression; Melatonin; Agomelatine Neurociências Depressão; Melatonina; Agomelatina |
description |
Depression is one of the major mental illnesses of the century, being one of the major causes of morbidity and disability. Antidepressants (AD) currently on the market seem to increase concentrations of monoamines in the brain (dopamine, noradrenaline and serotonin). However, ADs have unwanted side effects, and this has motivated research on drugs with differentiated mechanisms of action. It is known that in the depressive state the circadian cycle is altered, resulting in damages in the sleep phases and wake, and consequently in the concentrations of melatonin (MEL). MEL is an important hormone related to the synchronization of the circadian cycle, and is closely linked with depressive states and insomnia. With these data, the objective of this work was to investigate through a literature review, the relationship of the melatoninergic system with depression and treatment with agomelatine. As a method, studies related to the descriptors: “depression and melatonin” were searched in the search platforms:”Scielo, PubMed and BVS (lilacs)”. The results obtained show that, of the studies evaluated, they mostly refers to agomelatine, an AD drug analogous to melatonin. AGOM has promising results in clinical and preclinical research to treat problems related to insomnia and depression, representing an innovation in drugs for this therapeutic purpose. It was concluded that the melatoninergic system is closely linked to depressive states and agomelatine presents as a promising drug for the treatment of depression associated with sleep and virile cycle disorders. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-02-26 |
dc.type.none.fl_str_mv |
|
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487 10.18316/sdh.v9i1.5487 |
url |
https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487 |
identifier_str_mv |
10.18316/sdh.v9i1.5487 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487/pdf |
dc.rights.driver.fl_str_mv |
Direitos autorais 2021 Saúde e Desenvolvimento Humano info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos autorais 2021 Saúde e Desenvolvimento Humano |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade LaSalle - Unilasalle Canoas |
publisher.none.fl_str_mv |
Universidade LaSalle - Unilasalle Canoas |
dc.source.none.fl_str_mv |
Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021) Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021) 2317-8582 reponame:Saúde e Desenvolvimento Humano instname:Universidade La Salle (UNILASALLE) instacron:UNILASALLE |
instname_str |
Universidade La Salle (UNILASALLE) |
instacron_str |
UNILASALLE |
institution |
UNILASALLE |
reponame_str |
Saúde e Desenvolvimento Humano |
collection |
Saúde e Desenvolvimento Humano |
repository.name.fl_str_mv |
Saúde e Desenvolvimento Humano - Universidade La Salle (UNILASALLE) |
repository.mail.fl_str_mv |
sdh@unilasalle.edu.br |
_version_ |
1749120543934644224 |